drugset / Trial / NCT00362258
I PREVENT - Irbesartan In Hypertensive Diabetic Patients
Non-randomizedSingle-groupOpen-labelTreatment
Summary
* To evaluate Blood Pressure (BP) reduction to the targeted values (Systolic BP ≤ 130 mmHg and Diastolic BP ≤ 80 mmHg) in hypertensive type 2 diabetic patients. * To evaluate the benefit of Irbesartan in the reduction of microalbuminuria from baseline (if any at the inclusion visit) in this population. * To demonstrate the safety of Irbesartan in this population.
Timeline
- Start
- 2006-02
- Primary completion
- 2008-09
- Completion
- 2008-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irbesartan | Small molecule | 150 mg | Oral |
| Subject | Irbesartan | Small molecule | 300 mg | Oral |
| Background | Hydrochlorothiazide | Unknown | 12.5 mg | Oral |